摘要
目的系统分析^(89)Sr、双膦酸盐及^(89)Sr联合双膦酸盐(联合用药)治疗肿瘤多发性骨转移的疗效,并进行Meta分析。方法检索MEDLINE、EMBASE、The Cochrane Library、CBMdisc、CNKI,同时手检《同位素》、《肿瘤》、《中华核医学与分子影像杂志》、《中华放射肿瘤学杂志》,纳入对比分析^(89)Sr、双膦酸盐、联合用药治疗肿瘤多发性骨转移疗效的临床研究。对纳入研究进行质量评价,并应用Rev Man 5.0软件进行Meta分析。结果纳入随机对照研究7篇,半随机对照研究1篇,非随机对照研究7篇,共1 196例患者。Meta分析显示,联合用药治疗肿瘤多发性骨转移患者与分别单独使用89Sr或双膦酸盐相比,在缓解疼痛、提高患者生活质量和减少/缩小骨转移灶方面的差异有统计学意义(P<0.01)。结论联合用药可更有效地缓解疼痛,提高患者生活质量和减少/缩小转移灶。
Objective To assess the efficacy of SgSr, bisphosphonates and 89Sr plus bisphos- phonates （combined therapy） for patients with bone metastases. Methods Authors searched MED- LINE, EMBASE, the Cochrane Library, CBMdisc and CNKI. Isotopes, Tumor, Chinese Journal of Nuclear Medicine and Molecular Imaging , Chinese Journal of Radiation Oncology were manually searched. Effects of 89Sr, bisphosphonates and combined therapy for bone metastases were analyzed. The quality of each study was evaluated. Meta-analysis was performed by RevMan 5.0 software. Re- sults Totally 7 randomized controlled trials, 1 semi-randomized controlled trial and 7 non-random- ized controlled trials were selected （1196 patients）. Compared with S9Sr and bisphosphonates, com- bined therapy was stronger in bone pain relief, improving life quality and decreasing lesions or reducing volume of bone metastases （P 〈0.01 ）. Conclusion Combined therapy can relieve bone pain, improve life quality and decrease lesions or reduce volume of bone metastases.
出处
《实用临床医药杂志》
CAS
2017年第11期54-58,共5页
Journal of Clinical Medicine in Practice
基金
四川省卫生厅科研课题(130911)
